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Abstract
Background
Chronic infection by Trypanosoma cruzi could cause heart conduction disturbances. We
sought to analyze electrocardiographic abnormalities among children with chronic T. cruzi
infection with and without trypanocidal treatment with benznidazole.
Methodology/Principal Findings
We studied 111 children 6–16 years of age with asymptomatic chronic T. cruzi infection who
were recruited in 1991–1992 in Salta, Argentina. Most children were randomly assigned to
benznidazole 5 mg/Kg/day (n = 47) or matching placebo (n = 48) for 60 days. Remaining
children (n = 16) received treatment with benznidazole 5 mg/Kg/day open-label. Electrocar-
diograms were obtained at baseline and in 1995–1996, 1998, 2000 and 2005, and were
analyzed using the Buenos Aires method. Among the 94 children with an electrocardiogram
at baseline, 8 (8.5%) had electrocardiographic abnormalities, including 4 (4.7%) children
with right bundle branch block. Proportion of abnormal electrocardiograms in the full popula-
tion (n = 111) remained constant over time (media follow-up 8.6 years). Multivariable
adjusted prevalence ratios (95% confidence interval [95%CI]) for electrocardiographic
abnormalities in 1995–1996, 1998, 2000 and 2005 comparing children treated with benzni-
dazole versus those not treated were 2.76 (0.66, 11.60), 2.33 (0.44, 12.31), 3.06 (0.48,
19.56), and 1.94 (0.33, 11.25), respectively. Among the 86 children with a normal electro-
cardiogram at baseline, 16 (18.6%) developed electrocardiographic abnormalities during
follow-up. The multivariable adjusted hazard ratio for incident electrocardiographic abnor-
malities comparing children treated with benznidazole versus those not treated was 0.68
(95%CI: 0.25, 1.88).
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Conclusions/Significance
Electrocardiographic abnormalities are frequent among children with chronic T. cruzi infec-
tion. Treatment with benznidazole for 60 days may not be associated with less electrocar-
diographic abnormalities.
Author Summary
There are few data available on the natural history of electrocardiographic abnormalities
among children with chronic Trypanosoma cruzi infection. Also, few studies analyzed the
effect of benznidazole to prevent electrocardiographic abnormalities in this population. In
the current study, electrocardiographic abnormalities were frequent among children with
chronic T. cruzi infection. Results from the current study also suggest that treatment with
benznidazole may not be associated with less electrocardiographic abnormalities. The cur-
rent study highlights the need of further research to prevent cardiovascular manifestations
associated with chronic T. cruzi infection.
Introduction
Chagas’ disease is a chronic condition characterized by cardiovascular, digestive and neurologic
manifestations, which is caused by a vector borne parasitic infection (Trypanosoma cruzi)
endemic in Latin America [1]. Chagas’ disease is an important cause of premature death, dis-
ability, reduced quality of life and high costs for health systems in endemic countries [1, 2].
Emigration from Latin America (mainly to US, Canada, Europe and Australia) as well as alter-
native routes of transmission (i.e., vertical or through blood transfusion) have transformed
Chagas’ disease in a major global threat [3–6]. Every year, Chagas’ disease is responsible for
806,170 disability-adjusted life-years lost and US$ 627.46 million in direct healthcare costs
worldwide, with more than 14% of these costs emanating from non-endemic countries [7].
Most individuals with Chagas’ disease have chagasic cardiomyopathy [1, 8, 9]. Chagasic car-
diomyopathy usually appears in the adulthood, after 10 to 20 years of chronic infection by T.
cruzi [1]. However, early stages of chagasic cardiomyopathy can also be detected among chil-
dren or adolescents [10]. Chagasic cardiomyopathy is commonly preceded by heart conduction
disturbances, which can be detected through electrocardiography [9, 11–13]. Electrocar-
diographic abnormalities are considered an important marker of chagasic cardiomyopathy
severity and progression [9, 11].
Benznidazole is effective to induce parasite clearance [14–17] and is recommended for treat-
ment of acute, congenital and reactivated T. cruzi infection as well as among children with
chronic infection [18, 19]. Evidence from animal models suggest that treatment with benznida-
zole could prevent or control chagasic cardiomyopathy [20], although results from observa-
tional studies have been controversial [16]. Treatment with benznidazole for 60 days was not
effective to prevent clinical progression in adults with chagasic cardiomyopathy (mean age 55
years) in a large randomized clinical trial (Benznidazole Evaluation for Interrupting Trypano-
somiasis, BENEFIT, NCT00123916) [21]. These results support current guidelines which do
not recommend treatment with benznidazole among individuals with chronic T. cruzi infec-
tion 50 years of age or older or with advanced cardiomyopathy [18, 22].
Few studies analyzed the characteristics and natural history of electrocardiographic abnor-
malities among children with chronic T. cruzi infection and the effect associated with treatment
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with benznidazole [16, 19]. The main objective of the present study was to investigate the pres-
ence of electrocardiographic abnormalities in a cohort of children with chronic T. cruzi infec-
tion, some of whom received treatment with benznidazole. We hypothesized that
electrocardiographic abnormalities will be frequent among children with chronic T. cruzi infec-
tion and less common among those treated with benznidazole versus those not treated.
Methods
Population and procedures
We conducted a retrospective cohort study using data collected during a double-blind random-
ized controlled clinical trial with extended follow-up. The clinical trial was conducted in Salta
province, Argentina from 1991 through 1996 and was aimed at investigating the parasite clear-
ance and safety associated with treatment with benznidazole among children 6 to 12 years of
age with asymptomatic chronic infection by T. cruzi [15]. The region where the study was con-
ducted had continuous surveillance for T. cruzi vectors by sanitary agents since 1982, and the
possibility of reinfection after treatment was considered low. During enrolment in 1991–1992,
children attending local elementary schools were screened by history, physical examination
and 3 serology tests for T. cruzi using different techniques: indirect hemagglutination inhibi-
tion, indirect immunofluorescence assay, and enzyme-linked immunosorbent assay. Of rele-
vance to the current analysis, information on age, sex, body weight and place of residence was
collected. Children were considered eligible for the clinical trial if they had chronic infection by
T. cruzi, defined by at least 2 positive serology tests using different techniques. Exclusion crite-
ria were presence of any acute infection or chronic condition, or unstable residence. Children
with Chagas’ disease, defined by the presence of cardiovascular, digestive or neurologic symp-
toms, were excluded from the study.
Children included in the clinical trial were matched by age and place of residence, and ran-
domly assigned to benznidazole 5 mg/Kg/day (benznidazole group, n = 55) or placebo (placebo
group, n = 51) for 60 days. Participants were followed for 48 months through 1995–1996. At
the end of the clinical trial, all participants in the placebo group were offered treatment with
benznidazole if follow-up for adverse events was considered feasible. A total of 18 children in
the placebo group completed a properly documented treatment with benznidazole open-label
in 1997, following the same treatment protocol as in the clinical trial. No treatment with benz-
nidazole was documented among the remaining 33 children assigned to placebo. An enzyme-
linked immunosorbent assay using a flagellar calcium-binding protein F29 (F29 ELISA) and
xenodiagnosis were performed in children included in the clinical trial in 2005.
A cohort of 19 children with asymptomatic chronic infection by T. cruzi who completed the
study anamnesis, physical examination and serology tests but were not included in the clinical
trial received treated with benznidazole open-label 5 mg/Kg/day for 60 days in 1991–1992
(benznidazole cohort). Reasons for exclusion from the clinical trial included age<6 or>12
years, abnormal laboratory parameters (leukocytosis or anemia), intestinal parasitosis, and
unstable residence.
Electrocardiograms were obtained from children enrolled in the clinical trial and in the
benznidazole cohort in 1991–1992, 1995–1996, 1998, 2000 and 2005. For the present analysis,
we included children enrolled in the clinical trial or in the benznidazole cohort who had at
least 1 valid electrocardiogram to assess electrocardiographic abnormalities.
Ethics statement
Written informed consent to participate in the study was obtained from legal guardians before
assessment for enrollment and once again before randomization among those included in the
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clinical trial. Written informed consent to participate in subsequent examinations (i.e., in 1998,
2000 and 2005) was obtained from the participant or the legal guardian, according the partici-
pant’s age. The protocol was reviewed and approved by the Institutional Review Board of the
“Instituto Nacional de Chagas Dr. Mario Fatala Chaben”, Buenos Aires, Argentina before the
study initiation. Study procedures were conducted in accordance with the principles stated in
the Declaration of Helsinki.
Variables included in the analysis
All electrocardiograms were analyzed by the same cardiologist (NP) using the Buenos Aires
method [23]. The Buenos Aires method is an electrocardiographic recording and reading guide
designed for epidemiological studies on Chagas’ disease. This method analyzes 5 electrocar-
diographic measurements and 48 items classified into 9 diagnostic categories: overall assess-
ment, rhythm, supraventricular arrhythmias, ventricular arrhythmias, atrioventricular
conduction disturbances, ventricular conduction defects, abnormal initial QRS complex, pri-
mary ST-T wave changes, and miscellaneous. The inter-rater agreement to identify electrocar-
diographic abnormalities using the Buenos Aires method is substantial (kappa statistic: 0.66,
standard error: 0.02) [23]. Electrocardiograms with missing date or coded as not evaluable by
the cardiologist were excluded from the current analysis. Electrocardiographic abnormalities
were defined by any abnormal finding identified using the Buenos Aires method.
Potential confounders assessed at baseline which were used for statistical adjustment in the
present analysis include age, gender, body weight and rural residence.
Statistical analysis
Baseline characteristics of participants included in the current analysis who were randomly
assigned to benznidazole and placebo, separately, and those in the benznidazole cohort are
reported using median and 25th-75th percentiles for continuous variables, and percentage for
binary variables. Differences between groups were analyzed using Kruskal-Wallis or Fisher’s
exact tests, as appropriated.
We calculated the proportion of electrocardiograms with electrocardiographic abnormali-
ties in each assessment period (i.e., 1991–1992, 1995–1996, 1998, 2000 and 2005), separately.
Some participants have more than 1 electrocardiogram recorded in the same period. Therefore,
we used a mixed effect model with random intercept to estimate appropriated 95% confidence
intervals (CI) taking into account repeated measurements from a same participant. We used
the last observation carried forward method for the main analysis because some participants
did not have an electrocardiogram in each assessment period. The regression model was fit
using the maximum likelihood method with a binomial distribution and log link, and including
the assessment periods as dummy variables with 1991–1992 as the reference. We used least-
squares means to estimate the proportion and 95% CI for electrocardiographic abnormalities
in each period. We tested for a trend in the proportion of electrocardiograms with electrocar-
diographic abnormalities over time by analyzing the assessment period as an ordinal variable.
We used a panel analysis and Poisson regression models with robust variance to analyze the
association between treatment with benznidazole and electrocardiographic abnormalities. We
used Poisson regression models because log-binomial regression models including multivari-
able adjustment did not converge. Model 1 included terms for each assessment period using
dummy variables as described above and an indicator variable for treatment with benznidazole.
Model 2 included variables in Model 1 plus age, gender, body weight and rural residence. All
models included interactions between each assessment period and treatment with benznidazole
to estimate the effect modification associated with benznidazole after baseline [24]. Prevalence
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ratios and 95% CI for electrocardiographic abnormalities were estimated after exponentiation
of coefficients for the interactions between the assessment periods and treatment with benzni-
dazole. These prevalence ratios represent the relative effect of benznidazole on electrocar-
diographic abnormalities after adjusting for baseline differences in the proportion of
electrocardiograms with abnormalities between children treated and not treated with
benznidazole.
For our main analysis, we considered that children randomly assigned to benznidazole in
the clinical trial and those in the benznidazole cohort were treated with this medication (inten-
tion-to-treat analysis). Several sensitivity analyses of the association between treatment with
benznidazole and electrocardiographic abnormalities were conducted. First, we repeated the
analysis without using the last observation carried forward method. Second, we conducted a
per-protocol analysis, considering children who did not complete 30 days of treatment with
benznidazole as not treated, and children who received treatment with benznidazole in 1997 as
treated in 1998, 2000 and 2005. We used 30 days to determine whether children were treated as
prior studies have shown that a treatment with benznidazole shorter than 60 days can be effec-
tive to induce T. cruzi clearance [25, 26]. Finally, we repeated the analysis limited to children
enrolled in the randomized controlled clinical trial.
We conducted analyses limited to children without electrocardiographic abnormalities at
baseline. Baseline characteristics of participants in these analyses as well as the characteristics
of incident electrocardiographic abnormalities and the proportion of electrocardiograms with
abnormalities over time were calculated as described above. We used a Weibull regression
model (accelerated failure time) to conduct an interval-censoring analysis of the association
between treatment with benznidazole and incident electrocardiographic abnormalities among
children with a normal electrocardiogram at baseline [27]. Hazard ratios and 95% CI for inci-
dent electrocardiographic abnormalities associated with treatment with benznidazole were cal-
culated as described by Collett [28]. In addition to a crude model, a multivariable adjusted
model was fit, including adjustment for age, gender, body weight and rural residence. Finally,
we analyzed F29 ELISA and xenodiagnosis results in 2005 among children treated with benzni-
dazole in the clinical trial who had incident electrocardiographic abnormalities.
All statistical analyses were performed using SAS v. 9.4 (SAS Institute Inc., Cary, NC). All
tests were 2-sided and used a level of significance alpha<0.05.
Results
Children in the benznidazole cohort (n = 19) were similar to participants enrolled in the clini-
cal trial (n = 106) regarding gender (47.4% vs 52.8% females, Fisher’s exact test p-value: 0.80)
and place of residence (57.9% vs 45.3% rural residents, p-value: 0.33), but were older (median
age in years [25th-75th percentiles]: 10 [9–14] vs 10 [8–11], Wilcoxon rank-sum test p-value:
0.05). Between 1991 and 2005, 500 electrocardiograms were obtained from this population. We
excluded electrocardiograms with missing date (n = 1) and those coded as not evaluable by the
cardiologist (n = 14). After these exclusions, 111 children had at least 1 valid electrocardiogram
during the study period (485 electrocardiograms in total) and were included in the current
analysis. The distribution of children and electrocardiograms included in the analysis is shown
in Fig 1. The number of children who participated at follow-up examinations and had an elec-
trocardiogram was reduced over time, mainly because migration.
Children included in the analysis who were assigned to the benznidazole (n = 48) and pla-
cebo (n = 47) groups of the clinical trial, separately, and those in the benznidazole cohort
(n = 16) were similar in age, body weight, gender and rural residence (Table 1, top panel).
However, children in the benznidazole cohort had less electrocardiograms during follow-up as
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compared to those enrolled in the clinical trial. Median follow-up (25th-75th percentile) was 8.6
(7.1–14.1) years.
A total of 94 children had an electrocardiogram in 1991–1992, including 8 (8.5%) children
with electrocardiographic abnormalities (Table 2). Most common electrocardiographic abnor-
malities included rR’ or R wave in V1 (i.e., right bundle branch block) and left anterior fascicu-
lar block. Proportion of electrocardiograms with electrocardiographic abnormalities reminded
relatively stable across assessment periods, ranging from 8.6% (95% CI: 4.3%-16.7%) in 1991–
1992 to 11.3% (95% CI: 6.5%-18.9%) in 1998 (Fig 2, left panel).
The prevalence of electrocardiograms with abnormalities was higher among children
treated with benznidazole compared with those not treated in all assessment periods following
the baseline evaluation (Table 3). Prevalence ratios for electrocardiographic abnormalities
Fig 1. Flowchart of participants included in the analysis. ECG: electrocardiogram.
doi:10.1371/journal.pntd.0004651.g001
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associated with treatment with benznidazole were not statistically significant in any post-base-
line assessment. Results were similar in sensitivity analyses.
Baseline characteristics of the 86 children without electrocardiographic abnormalities in
1991–1992 are shown in Table 1, bottom panel. The proportion of electrocardiograms with
electrocardiographic abnormalities increased over time in this population (Fig 2, right panel).
A total of 16 (18.6%) children developed incident electrocardiographic abnormalities during
follow-up, including 8 participants who received treatment with benznidazole in 1991–1992
(Table 4). Among those with incident electrocardiographic abnormalities, 4 children (3 chil-
dren treated with benznidazole) developed rR’ or R in V1. The crude hazard ratio for incident
electrocardiographic abnormalities comparing children treated with benznidazole versus those
not treated was 0.74 (95% CI: 0.28–1.97, p-value: 0.54). After adjustment for age at baseline,
gender, rural residence and body weight, the hazard ratio for incident electrocardiographic
abnormalities associated with treatment with benznidazole was 0.68 (95% CI: 0.25–1.88, p-
value: 0.46). All of the 5 children treated with benznidazole in the clinical trial who had inci-
dent electrocardiographic abnormalities and completed a F29 ELISA and xenodiagnosis test in
2005 had negative results for T. cruzi infection.
Discussion
We analyzed the characteristics and frequency of electrocardiographic abnormalities among
children with chronic T. cruzi infection and the effect associated with treatment with benznida-
zole. In our analysis, children with chronic T. cruzi infection frequently presented or developed
Table 1. Baseline characteristics of children included in the analysis (n = 111) and those without electrocardiographic abnormalities at baseline
(n = 86).
Double-blind randomized clinical trial
Assigned to
placebo
Assigned to
benznidazole
Benznidazole
cohort
p-
value
Children included in the analysis, n 47 48 16
n (%)
Female 23 (49) 25 (52) 8 (50) 0.97
Rural residence 22 (49) 20 (42) 10 (63) 0.34
Median (25th-75th percentiles)
Age, years 10 (9, 11) 10 (8, 12) 10 (9, 14) 0.37
Weight, Kg 30 (24, 38) 31 (26, 38) 34 (26, 47) 0.31
Number of electrocardiograms 5 (4, 6) 5 (4, 6) 4 (2, 4) 0.03
Follow-up, years 7.6 (7.1, 14.1) 8.6 (7.1, 14.1) 11.3 (7.0, 14.0) 0.43
Children without electrocardiographic abnormalities at
baseline, n
38 37 11
n (%)
Female 20 (53) 17 (46) 7 (64) 0.63
Rural residence 16 (42) 17 (46) 7 (64) 0.50
Median (25th-75th percentiles)
Age, years 10 (8, 11) 10 (8, 12) 10 (9, 14) 0.38
Weight, Kg 30 (24, 37) 31 (25, 38) 33 (25, 49) 0.33
Number of electrocardiograms 5 (4, 6) 5 (4, 6) 4 (3, 4) 0.04
Follow-up, years 8.1 (7.1, 14.1) 13.0 (7.1, 14.1) 8.6 (6.9, 14.0) 0.44
Note: Variables reported have no missing data.
doi:10.1371/journal.pntd.0004651.t001
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electrocardiographic abnormalities. Most of these electrocardiographic abnormalities, includ-
ing right bundle branch block, and left anterior fascicular block, are more common among
individuals with chronic T. cruzi infection [29]. After statistical adjustment, treatment with
benznidazole for 60 days was not associated with less electrocardiographic abnormalities as
compared with no treatment over a median follow-up of 8.6 years. We found no evidence of
treatment failure among children with incident electrocardiographic abnormalities who com-
pleted treatment with benznidazole at baseline. These results should be interpreted in the con-
text of the few number of participants analyzed, the number of electrocardiographic
abnormalities and the long term evolution of chagasic cardiomyopathy.
Table 2. Description of baseline electrocardiograms in 1991–1992 according the Buenos Aires
method (n = 94).
Buenos Aires method All children (n = 94)
Electrocardiographic measurements Median / 25th and 75th percentiles / minimum and
maximum
Heart rate, beats per minute 86 / 77, 96 / 63, 123
PR interval, seconds/100 0.12 / 0.12, 0.14 / 0.10, 0.20
QRS duration, seconds/100 0.07 / 0.06, 0.08 / 0.05, 0.08
QRS axis, degrees 60 / 45, 60 / -45, 150
Ventricular extrasystoles, n 0 / 0, 0 / 0, 0
Electrocardiographic items* n (%)
Overall assessment
Normal 86 (91)
Abnormal 8 (9)
Rhythm
Sinus 94 (100)
Supraventricular arrhythmias
None 92 (98)
Supraventricular extrasystoles 2 (2)
Ventricular arrhythmias
None 94 (100)
Atrioventricular conduction disturbances
None 94 (100)
Ventricular conduction defects
None 86 (92)
rR’ or R in V1 (i.e., right bundle branch
block)
4 (4)
Left anterior fascicular block 3 (3)
Noncodiﬁable 1 (1)
Abnormal initial QRS complex
None 92 (98)
Noncodiﬁable 2 (2)
Primary ST-T wave changes
None 93 (99)
Noncodiﬁable 1 (1)
Miscellaneous
None 93 (99)
Right ventricular hypertrophy 1 (1)
* Only electrocardiographic items with non-zero values are displayed for simplicity.
doi:10.1371/journal.pntd.0004651.t002
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Treatment with benznidazole is currently recommended in acute, congenital and reacti-
vated infection by T. cruzi, and among children with chronic infection [18, 19, 30, 31]. The rec-
ommendation to treat children with chronic T. cruzi infection is based on 2 clinical trials
conducted in the 1990s which found that benznidazole is effective to induce T. cruzi clearance
in this population [14, 15]. However, these studies have not shown that treatment with benzni-
dazole can prevent heart conduction disturbances or chagasic cardiomyopathy. In 1991, de
Andrade et al. carried out a clinical trial including 130 children 7 to 12 years of age with
chronic T. cruzi infection who were randomly assigned 1:1 to treatment with benznidazole 7.5
mg/Kg/day or placebo for 60 days [14]. Over 3 years of follow-up, 1 child in the treatment
group and 4 children in the control group developed a complete right bundle branch block (p-
value: 0.36). None of the children showed evidence of chagasic cardiomyopathy after 6 years of
follow-up in the extension study [32]. Using data from the other clinical trial conducted in the
1990s, we observed no difference in the presence of a broader spectrum of electrocardiographic
abnormalities between children with chronic T. cruzi infection who were and were not treated
with benznidazole. Results from these studies are important considering the few data available
about the natural history of electrocardiographic abnormalities and the effect of treatment with
benznidazole on heart conduction disturbances among children with chronic T. cruzi infection.
Taken together, results from these studies suggest that treatment with benznidazole in the cur-
rent scheme of 60 days may not prevent electrocardiographic abnormalities in this population.
Few studies have investigated the efficacy of benznidazole to prevent electrocardiographic
abnormalities or Chagas’ heart disease progression among adults [16, 33, 34]. In the BENEFIT
trial, treatment with benznidazole did not reduce the risk for clinical outcomes compared with
placebo among 2,854 adults with chagasic’ cardiomyopathy. After 7 years of follow-up, the haz-
ard ratio for death, cardiac arrest, insertion of a pacemaker or an implantable cardioverter–defi-
brillator, sustained ventricular tachycardia, cardiac transplantation, new heart failure, stroke,
transient ischemic attack, or a thromboembolic event associated with benznidazole was 0.93
(95% CI: 0.81–1.07). These results support some current guidelines which do not recommend
treatment with benznidazole among adults more than 50 years old with chronic T. cruzi infection
given their lower rate of seroconversion and a higher risk for side effects compared with children
[18, 19, 35]. Results from TRAENA (NCT02386358), another large randomized clinical trial
Fig 2. Proportion of electrocardiogramswith abnormalities by assessment period among all children included in the analysis (n = 111) and
children without electrocardiographic abnormalities at baseline (n = 86). Labels represent proportion (95% confidence intervals). *Using the last
observation carried forward method. ECG: electrocardiogram.
doi:10.1371/journal.pntd.0004651.g002
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designed to investigate the efficacy of benznidazole to prevent major cardiovascular outcomes
among adults with Chagas’ disease, are expected to be published by the end of 2016 [36].
In our analysis, we found no evidence of persistent T. cruzi infection among children with
incident electrocardiographic abnormalities who received treatment with benznidazole.
Table 3. Association between treatment with benznidazole and electrocardiographic abnormalities according the Buenos Aires method.
Panel 1 Panel 2 Panel 3 Panel 4 Panel 5
1991–1992 1995–1996 1998 2000 2005 p-value
Main analysis (n = 111)
Proportion of electrocardiograms with electrocardiographic abnormalities, % (95% CI)
Treatment with benznidazole 6.8% (2.2%,
20.9%)
12.4% (6.1%,
25.1%)
13.3% (7.0%,
25.5%)
12.9% (6.7%,
24.7%)
10.9% (5.4%,
22.1%)
-
No treatment with
benznidazole
10.6% (4.4%,
25.5%)
6.6% (2.8%,
15.2%)
8.7% (3.4%,
22.2%)
6.4% (2.1%, 19.1%) 8.5% (3.3%,
21.8%)
-
Treatment with benznidazole vs no treatment, PR (95% CI)
Model 1 - 2.91 (0.74, 11.46) 2.37 (0.46, 12.25) 3.13 (0.50, 19.53) 1.99 (0.35, 11.35) 0.55
Model 2 - 2.76 (0.66, 11.60) 2.33 (0.44, 12.31) 3.06 (0.48, 19.56) 1.94 (0.33, 11.25) 0.63
Sensitivity analyses
Analysis without the last observation carried forward method (n = 111)
Proportion of electrocardiograms with electrocardiographic abnormalities, % (95% CI)
Treatment with benznidazole 6.8% (2.2%,
20.9%)
13.2% (6.5%,
26.8%)
17.0% (9.0%,
32.1%)
21.9% (11.3%,
42.2%)
12.9% (5.1%,
32.3%)
-
No treatment with
benznidazole
10.6% (4.4%,
25.5%)
6.8% (3.0%,
15.9%)
10.8% (4.3%,
27.4%)
5.3% (0.8%, 35.8%) 18.7% (6.7%,
52.3%)
-
Treatment with benznidazole vs no treatment, PR (95% CI)
Model 1 - 2.98 (0.75, 11.79) 2.44 (0.49, 12.17) 6.44 (0.57, 72.83) 1.07 (0.18, 6.27) 0.27
Model 2 - 2.95 (0.70, 12.51) 2.38 (0.47, 12.11) 6.55 (0.57, 75.31) 0.90 (0.14, 5.53) 0.26
Analysis per protocol (n = 111)
Proportion of electrocardiograms with electrocardiographic abnormalities, % (95% CI)
Treatment with benznidazole 7.2% (2.4%,
22.0%)
13.0% (6.4%,
26.4%)
13.2% (7.4%,
23.5%)
13.0% (7.8%, 21.7%)* -
No treatment with
benznidazole
10.0% (4.1%,
24.1%)
6.2% (2.7%,
14.3%)
6.7% (1.7%,
25.6%)
1.7% (0.2%, 11.7%)* -
Treatment with benznidazole vs no treatment, PR (95% CI)
Model 1 - 2.37 (0.73, 7.69) 1.78 (0.47, 6.83) 8.65 (0.89, 84.31)* 0.21
Model 2 - 2.56 (0.77, 8.59) 1.86 (0.42, 8.21) 8.63 (0.82, 90.95)* 0.27
Restricted to children enrolled in the randomized controlled clinical trial (n = 95)
Proportion of electrocardiograms with electrocardiographic abnormalities, % (95% CI)
Treatment with benznidazole 6.6% (1.8%,
24.4%)
12.8% (5.9%,
27.6%)
15.2% (7.7%,
30.2%)
10.6% (4.6%,
24.4%)
8.3% (3.3%,
21.4%)
-
No treatment with
benznidazole
10.6% (4.4%,
25.5%)
6.6% (2.8%,
15.2%)
8.7% (3.4%,
22.3%)
6.4% (2.1%, 19.2%) 8.5% (3.3%,
21.8%)
-
Treatment with benznidazole vs no treatment, PR (95% CI)
Model 1 - 3.15 (0.65, 15.19) 2.83 (0.46, 17.26) 2.70 (0.37, 19.87) 1.58 (0.23, 10.75) 0.60
Model 2 - 2.92 (0.56, 15.15) 2.72 (0.44, 16.85) 2.59 (0.34, 19.54) 1.52 (0.22, 10.52) 0.68
Model 1 adjusts for the difference in the proportion of electrocardiograms with electrocardiographic abnormalities in 1991–1992 between children treated
and not treated with benznidazole. Model 2 adjusts for covariates in Model 1 plus age, gender, rural residence and body weight.
* Electrocardiograms in panels 4 and 5 were combined to prevent cells with 0 cases
CI: conﬁdence intervals; PR: prevalence ratio.
doi:10.1371/journal.pntd.0004651.t003
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However, conventional tests for T. cruzi infection (i.e., serology tests, xenodiagnosis and poly-
merase chain reaction [PCR]) have important limitations to determine a complete parasite
elimination following treatment with benznidazole [37]. Specifically, serology tests may remain
positive several years after treatment with benznidazole, and xenodiagnosis and PCR are nega-
tive in many individuals with chronic T. cruzi infection [19, 38]. Prior studies have shown a
trypanocidal effect of benznidazole among individuals with chronic T. cruzi infection using
serology tests, xenodiagnosis and PCR [14–17, 34]. However, some individuals may remain
with persistent T. cruzi infection after treatment. In the BENEFIT trial, 53.3% of participants
with a positive PCR test at baseline who received treatment with benznidazole had a positive
PCR test after 5 years of follow-up [21]. Even a few number of T. cruzi specimens could be
enough to maintain an autoimmune response with production of antibodies against nervous
and cardiac muscle which could play an important role in the development and progression of
heart conduction disturbances and chagasic cardiomyopathy [30, 33, 39]. This could have con-
tributed to an apparent lack of efficacy of benznidazole to prevent electrocardiographic abnor-
malities or chagasic cardiomyopathy in prior studies. Future studies should focus on
developing diagnostic methods with high sensitivity and specificity to detect persistent T. cruzi
infection after treatment with trypanocidal drugs as well as to determine whether individuals
with persistent T. cruzi infection would benefit from retreatment.
Most participants included in the present analysis were initially enrolled in a clinical trial
and all procedures for data collection followed the same study protocol. Also, treatment with
benznidazole was performed in accordance with current recommendations [18, 19, 35].
Table 4. Incident electrocardiographic abnormalities among children with a normal electrocardiogram at baseline (1991–1992) according the Bue-
nos Airesmethod (n = 86).
No treatment with benznidazole (n = 38) Treatment with benznidazole (n = 48)
Electrocardiographic items n (%) n (%)
Overall assessment
Abnormal 8 (21) 8 (17)
Rhythm
Atrial ectopic 1 (3) 0 (0)
Supraventricular arrhythmias
Supraventricular extrasystoles 1 (3) 0 (0)
Other atrial arrhythmias 0 (0) 1 (2)
Ventricular arrhythmias
Simple ventricular extrasystoles 0 (0) 2 (4)
Atrioventricular conduction disturbances
Ventricular pre-excitation 1 (3) 0 (0)
Ventricular conduction defects
rR’ or R in V1 (including right bundle branch block) 1 (3) 3 (6)
Left anterior fascicular block 1 (3) 0 (0)
Left posterior fascicular block 0 (0) 1 (2)
Nonspeciﬁc intraventricular conduction defect 1 (3) 0 (0)
Abnormal initial QRS complex
Present 1 (3) 0 (0)
Miscellaneous
Right ventricular hypertrophy 1 (3) 1 (2)
P wave 1 (3) 0 (0)
Note: only items with abnormal ﬁndings are displayed for simplicity.
doi:10.1371/journal.pntd.0004651.t004
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Despite these strengths, results from the present analysis should be interpreted in the context
of potential limitations. Following young populations in low resource settings is challenging
and some study participants were lost during follow-up, mainly because migration. Only few
covariates were available for statistical adjustment for potential confounders, which is related
to the fact that risk factors for chagasic cardiomyopathy among individuals with chronic T.
cruzi infection remain largely unknown. Several factors may have contributed to attenuate a
possible association between treatment with benznidazole and lower risk for electrocar-
diographic abnormalities in our study. Some children who received treatment with benznida-
zole may have remained with persistent T. cruzi infection. We cannot exclude the possibility of
reinfection among children successfully treated with benznidazole, although this was consid-
ered unlikely. Also, some children who were analyzed as untreated in the present study may
have received treatment with benznidazole during follow-up, which was not documented.
Some electrocardiographic abnormalities observed in this analysis, including bundle branch
block, may be unrelated with T. cruzi infection as they may also be detected among uninfected
children [29, 40]. However, a prior study using the Buenos Aires method reported that electro-
cardiographic abnormalities, including bundle branch block and left anterior fascicular block,
are more common among individuals with chronic T. cruzi infection compared with unin-
fected controls [29]. Because the small sample size, our analysis had low statistical power to
exclude a clinically relevant effect to prevent electrocardiographic abnormalities associated
with treatment with benznidazole. For example, in our main analysis, the lower bound of the
95% CI for the prevalence ratio in the second assessment period was 0.66. This means that we
cannot exclude a reduction on the prevalence of electrocardiographic abnormalities associated
with benznidazole as large as 44%. Finally, because the study was conducted in a restricted geo-
graphic area, results may not be generalizable to children with chronic T. cruzi infection from
other regions.
Results from the present study should not be interpreted as indicative that children with
chronic T. cruzi infection should not be treated with benznidazole. Treatment with benznida-
zole among children with chronic T. cruzi infection can contribute to induce T. cruzi clearance
[14, 15], and reduce the number of incident cases by vertical transmission [41–43], blood trans-
fusion and organ transplant [3, 31]. Treatment with benznidazole can also contribute to reduce
the risk for a reactivation associated with immunodeficiency disorders or immunosuppression,
and reaching seroconversion could be beneficial for the wellbeing of children and their relatives
[31]. Instead, results from our study highlight the need for further research on prevention of
cardiovascular manifestations of Chagas’ disease which should be recognized in the agenda of
health research priorities in endemic countries [44]. Although many endemic countries have
implemented public health actions aimed to increase the use of benznidazole among children
with chronic T. cruzi infection, treated children may still contribute to high direct healthcare
costs because their higher risk for cardiovascular manifestations. Further longitudinal studies
are needed to investigate whether tripanocides with new schemes can prevent cardiovascular
outcomes beyond electrocardiographic abnormalities, including heart failure and sudden
death, among children with chronic T. cruzi infection. This is important because there are few
data available about the clinical significance of electrocardiographic abnormalities among chil-
dren with chronic T. cruzi infection as most studies on heart conduction disturbances and Cha-
gas disease have been conducted among adults [11, 13].
In conclusion, electrocardiographic abnormalities are common among children with
chronic T. cruzi infection. There are several reasons for indicating trypanocidal therapy among
children with chronic T. cruzi infection. However, results from the present study suggest that
treatment with benznidazole for 60 days may not be associated with a lower occurrence of elec-
trocardiographic abnormalities.
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